Related Experiment Video
Updated: Mar 21, 2026

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
Structural Determinants of p53-Independence in Anticancer Ruthenium-Arene Schiff-Base Complexes
Mun Juinn Chow1,2, Maria V Babak1, Daniel Yuan Qiang Wong1
1Department of Chemistry, National University of Singapore , 3 Science Drive 3, 117543 Singapore.
Abstract:
p53 is a key tumor suppressor gene involved in key cellular processes and implicated in cancer therapy. However, it is inactivated in more than 50% of all cancers due to mutation or overexpression of its negative regulators. This leads to drug resistance and poor chemotherapeutic outcome as most clinical drugs act via a p53-dependent mechanism of action. An attractive strategy to circumvent this resistance would be to identify new anticancer drugs that act via p53-independent mode of action. In the present study, we identified 9 Ru (II)-Arene Schiff-base (RAS) complexes able to induce p53-independent cytotoxicity and discuss structural features that are required for their p53-independent activity. Increasing hydrophobicity led to an increase in cellular accumulation in cells with a corresponding increase in efficacy. We further showed that all nine complexes demonstrated p53-independent activity. This was despite significant differences in their physicochemical properties, suggesting that the iminoquinoline ligand, a common structural feature for all the complexes, is required for the p53-independent activity.
Insights
Researchers discovered novel ruthenium (II)-arene Schiff-base (RAS) complexes that kill cancer cells independently of the p53 gene. These new anticancer drugs overcome resistance, offering a promising alternative to p53-dependent therapies.
Area of Science:
- Oncology
- Medicinal Chemistry
- Molecular Biology
Background:
- The p53 tumor suppressor gene is crucial for cellular processes and cancer therapy.
- In over 50% of cancers, p53 is inactivated, leading to drug resistance and poor outcomes with p53-dependent drugs.
- There is a need for anticancer drugs with a p53-independent mechanism of action to overcome therapy resistance.
Purpose of the Study:
- To identify novel anticancer agents with p53-independent activity.
- To investigate the structural features of ruthenium (II)-arene Schiff-base (RAS) complexes responsible for p53-independent cytotoxicity.
- To explore the relationship between physicochemical properties, cellular accumulation, and efficacy of these complexes.
Main Methods:
- Synthesis and characterization of nine Ru (II)-Arene Schiff-base (RAS) complexes.
- Evaluation of cytotoxicity in cancer cell lines.
- Assessment of p53-dependency of the cytotoxic effect.
- Analysis of structure-activity relationships, including hydrophobicity and ligand effects.
Main Results:
- Nine RAS complexes were identified that induce significant p53-independent cytotoxicity.
- Increased hydrophobicity correlated with enhanced cellular accumulation and improved efficacy.
- All nine complexes exhibited p53-independent activity, irrespective of variations in physicochemical properties.
- The iminoquinoline ligand was identified as a key structural feature for p53-independent activity.
Conclusions:
- Ruthenium (II)-arene Schiff-base (RAS) complexes represent a promising class of anticancer agents with a p53-independent mode of action.
- Hydrophobicity and the presence of an iminoquinoline ligand are critical for the efficacy and cellular uptake of these novel compounds.
- These findings offer a potential strategy to circumvent p53-mediated drug resistance in cancer therapy.
Related Concept Videos
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Radical Reactivity: Steric Effects
Along with electronic...
Abnormal Proliferation
Negative Regulator Molecules
Treatment Resistant Cancers
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...

